BioCardia Secures US Patent for Innovative Heart Delivery Catheter

BioCardia, Inc., a biotech company specializing in cellular and cell-derived therapeutics for cardiovascular diseases, has been granted US Patent No. 12,311,127 for its Radial and Trans-endocardial Delivery Catheter, known as the Helix system. This minimally invasive catheter technology enables targeted delivery of biologic therapies directly to the heart, reducing off-target effects and eliminating the need for surgical access, thereby enhancing treatment safety and precision. The Helix catheter is a core component of BioCardia’s CardiAMP Cell Therapy program, aimed at treating ischemic cardiomyopathies and heart failure, with the company actively pursuing regulatory approvals for both the therapy and the delivery system. While analysts vary in their outlooks—some rating the stock as a Buy or Outperform with significant upside potential, others highlight financial instability and valuation concerns—the new patent strengthens BioCardia's intellectual property portfolio and supports its transition from development to commercialization. CEO Dr. Peter Altman emphasized the system's potential to improve patient outcomes and facilitate partnerships. Despite promising clinical advancements, BioCardia faces challenges including cash burn and weak financial metrics, which temper overall investor enthusiasm.